Greager J A, Brown J M, Pavel D G, Garcia J L, Blend M, Das Gupta T K
Cancer Immunol Immunother. 1986;23(2):148-54. doi: 10.1007/BF00199822.
The early localization of recurrent or metastatic sarcoma remains a challenging clinical problem. 125I-labeled monoclonal antibody (Mab) 19-24, produced in our laboratories against a human malignant fibrous histiocytoma, has been evaluated for detection of locally recurrent or metastatic disease in selected sarcoma patients. In vitro testing indicated various degrees of positive Mab reactivity with most sarcoma types, and low but significant reactivity with some nonsarcoma tumors and several normal tissues, including liver. The iodine-labeled Mab had an immunoreactivity of 90% and a high binding constant (8.1 X 10(9) M-1). Biodistribution studies of radioisotope in sarcoma patients showed rapid clearance of radiolabeled from the blood and uptake in tumor deposits, liver, and spleen. A differential in radioactivity kinetics between liver and tumor was also found. Serial patient scanning determined optimal imaging time to be between 24 and 48 h after i.v. infusion of the radiolabeled Mab. Analysis of tissues obtained during surgery (including a dual antibody-label study using a nonspecific Mab) showed selective localization of the Mab into the sarcoma deposits. Radiolabeled Mab shows potential as a clinically useful tool for localization of sarcoma deposits.
复发性或转移性肉瘤的早期定位仍然是一个具有挑战性的临床问题。我们实验室生产的针对人恶性纤维组织细胞瘤的125I标记单克隆抗体（Mab）19-24，已在选定的肉瘤患者中用于检测局部复发性或转移性疾病。体外测试表明，大多数肉瘤类型对Mab有不同程度的阳性反应，对一些非肉瘤肿瘤和包括肝脏在内的几种正常组织有低但显著的反应。碘标记的Mab免疫反应性为90%，结合常数高（8.1×10⁹ M⁻¹）。肉瘤患者放射性同位素的生物分布研究表明，放射性标记物从血液中快速清除，并在肿瘤沉积物、肝脏和脾脏中摄取。还发现肝脏和肿瘤之间的放射性动力学存在差异。对患者进行系列扫描确定，静脉注射放射性标记的Mab后24至48小时为最佳成像时间。对手术中获取的组织进行分析（包括使用非特异性Mab的双抗体标记研究）显示，Mab选择性地定位于肉瘤沉积物中。放射性标记的Mab显示出作为定位肉瘤沉积物的临床有用工具的潜力。
